Neurocrine Biosciences Stock Analysis

Neurocrine Stock Analysis Notes

About 95.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.44. Neurocrine Biosciences last dividend was issued on the 29th of December 1995. Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California. Neurocrine Bioscienc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 1150 people. To find out more about Neurocrine Biosciences contact Kevin Gorman at 858 617 7600 or learn more at https://www.neurocrine.com.

Neurocrine Biosciences Investment Alerts

Neurocrine Biosciences Upcoming and Recent Events

Neurocrine Largest EPS Surprises

View All Earnings Estimates

Neurocrine Biosciences Thematic Classifications

Neurocrine Stock Institutional Investors

Note, although Neurocrine Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Neurocrine Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 13.44 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Neurocrine Biosciences's market, we take the total number of its shares issued and multiply it by Neurocrine Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Neurocrine Profitablity

The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29.

Management Efficiency

Neurocrine Biosciences has return on total asset (ROA) of 0.0878 % which means that it generated a profit of $0.0878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1268 %, meaning that it created $0.1268 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024. Return On Capital Employed is likely to rise to 0.10 in 2024. At this time, Neurocrine Biosciences' Asset Turnover is fairly stable compared to the past year.

Technical Drivers

As of the 24th of April, Neurocrine Biosciences secures the Risk Adjusted Performance of (0), standard deviation of 1.49, and Mean Deviation of 1.14. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurocrine Biosciences, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to collect and analyze data for thirteen technical drivers for Neurocrine Biosciences, which can be compared to its peers in the industry. Please verify Neurocrine Biosciences market risk adjusted performance and treynor ratio to decide if Neurocrine Biosciences is priced some-what accurately, providing market reflects its recent price of 140.09 per share. Given that Neurocrine Biosciences has information ratio of (0.08), we recommend you to check Neurocrine Biosciences's last-minute market performance to make sure the company can sustain itself at a future point.

Neurocrine Biosciences Price Movement Analysis

Neurocrine Biosciences Insider Trading Activities

Neurocrine Biosciences Predictive Daily Indicators

Neurocrine Biosciences Corporate Filings

Neurocrine Biosciences Forecast Models

Neurocrine Biosciences' time-series forecasting models are one of many Neurocrine Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Neurocrine Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Neurocrine Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Neurocrine shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Neurocrine Biosciences. By using and applying Neurocrine Stock analysis, traders can create a robust methodology for identifying Neurocrine entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Neurocrine analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Neurocrine analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Neurocrine Biosciences stock analysis indicators help investors evaluate how Neurocrine Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Neurocrine Biosciences shares will generate the highest return on investment. By understating and applying Neurocrine Biosciences stock analysis, traders can identify Neurocrine Biosciences position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.